Search Videos by Topic or Participant
Browse by Series:

ADT in Prostate Cancer: Agonists Versus Antagonists

Panelists: Raoul S. Concepcion, MD, Urology Associates; Kenneth Kernen, MD, Michigan Institute of Urology; Bryan A. Mehlhaff, MD, Oregon Urology Institute;
Published: Friday, Mar 20, 2015
For High-Definition, Click
Androgen deprivation therapy (ADT) continues to be the mainstay for treating advancing prostate cancer. LHRH agonists, which have been used for decades, create a surge in the testosterone (T) level, and following, the hypothalamic pituitary-gonadal axis shuts down, Neal D. Shore, MD, states.

In 2009, the first LHRH antagonist was approved. Unlike agonists, these newer agents have the benefit of not creating a surge in testosterone The clinical endpoint for approval for both drug classes was T level <50. Shore notes that a level of 50 was used primarily because tests at that time were unable to detect levels lower than 50. However, it is now recognized that lower T levels, particularly in patients with castration-resistant prostate cancer, affect survival. Thus, he stresses the importance of checking patients’ T levels.

There is a lack of clear-cut evidence that a particular ADT strategy results in consistently lower T levels. Shore explains that the real question is whether there are other metrics, including follicle-stimulating hormone (FSH), the surge phenomenon, and the continuity of T suppression, which are capable of differentiating between the impact of agonists and that of antagonists. Additionally, researchers are investigating a possible difference in the agents’ risk profiles for cardiovascular events.
Slider Left
Slider Right
For High-Definition, Click
Androgen deprivation therapy (ADT) continues to be the mainstay for treating advancing prostate cancer. LHRH agonists, which have been used for decades, create a surge in the testosterone (T) level, and following, the hypothalamic pituitary-gonadal axis shuts down, Neal D. Shore, MD, states.

In 2009, the first LHRH antagonist was approved. Unlike agonists, these newer agents have the benefit of not creating a surge in testosterone The clinical endpoint for approval for both drug classes was T level <50. Shore notes that a level of 50 was used primarily because tests at that time were unable to detect levels lower than 50. However, it is now recognized that lower T levels, particularly in patients with castration-resistant prostate cancer, affect survival. Thus, he stresses the importance of checking patients’ T levels.

There is a lack of clear-cut evidence that a particular ADT strategy results in consistently lower T levels. Shore explains that the real question is whether there are other metrics, including follicle-stimulating hormone (FSH), the surge phenomenon, and the continuity of T suppression, which are capable of differentiating between the impact of agonists and that of antagonists. Additionally, researchers are investigating a possible difference in the agents’ risk profiles for cardiovascular events.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x